Fructose 1,6-bisphosphatase: getting the message across

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Fructose 1,6-bisphosphatase (FBPase) is a key enzyme in gluconeogenesis. It is a potential drug target in the treatment of type II diabetes. The protein is also associated with a rare inherited metabolic disease and some cancer cells lack FBPase activity which promotes glycolysis facilitating the Warburg effect. Thus, there is interest in both inhibiting the enzyme (for diabetes treatment) and restoring its activity (in relevant cancers). The mammalian enzyme is tetrameric, competitively inhibited by Fructose 2,6-bisphosphate and negatively allosterically regulated by AMP. This allosteric regulation requires information transmission between the AMP binding site and the active site of the enzyme. A recent paper by Topaz et al. (Bioscience Reports (2019) 39, pii:BSR20180960) has added additional detail to our understanding of this information transmission process. Two residues in the AMP binding site (Lys 112 and Tyr 113 ) were shown to be involved in initiating the message between the two sites. This tyrosine residue has recently be shown to be important with protein’s interaction with the antidiabetic drug metformin. A variant designed to increase metal ion affinity (M248D) resulted in a five-fold increase in enzymatic activity. Interestingly alterations of two residues at the subunit interfaces (Tyr 164 and Met 177 ) resulted in increased responsiveness to AMP. Overall, these findings may have implications in the design of novel FBPase inhibitors or activators.

Original languageEnglish
Article numberBSR20190124
Pages (from-to)1-5
Number of pages5
JournalBioscience Reports
Volume39
Issue number3
DOIs
Publication statusPublished - 6 Mar 2019

Fingerprint

Fructose-Bisphosphatase
Adenosine Monophosphate
Enzymes
Binding Sites
Allosteric Regulation
Gluconeogenesis
Metformin
Metabolic Diseases
Glycolysis
Hypoglycemic Agents
Type 2 Diabetes Mellitus
Tyrosine
Catalytic Domain
Neoplasms
Proteins
Metals
Ions
Pharmaceutical Preparations

Bibliographical note

©2019 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY).

Keywords

  • allosteric enzyme
  • FBPase
  • fructose 1
  • 6-bisphosphatase deficiency
  • gluconeogenesis
  • renal cancer
  • type II diabetes

Cite this

@article{8624063eca994730a2c8936753e723d1,
title = "Fructose 1,6-bisphosphatase: getting the message across",
abstract = "Fructose 1,6-bisphosphatase (FBPase) is a key enzyme in gluconeogenesis. It is a potential drug target in the treatment of type II diabetes. The protein is also associated with a rare inherited metabolic disease and some cancer cells lack FBPase activity which promotes glycolysis facilitating the Warburg effect. Thus, there is interest in both inhibiting the enzyme (for diabetes treatment) and restoring its activity (in relevant cancers). The mammalian enzyme is tetrameric, competitively inhibited by Fructose 2,6-bisphosphate and negatively allosterically regulated by AMP. This allosteric regulation requires information transmission between the AMP binding site and the active site of the enzyme. A recent paper by Topaz et al. (Bioscience Reports (2019) 39, pii:BSR20180960) has added additional detail to our understanding of this information transmission process. Two residues in the AMP binding site (Lys 112 and Tyr 113 ) were shown to be involved in initiating the message between the two sites. This tyrosine residue has recently be shown to be important with protein’s interaction with the antidiabetic drug metformin. A variant designed to increase metal ion affinity (M248D) resulted in a five-fold increase in enzymatic activity. Interestingly alterations of two residues at the subunit interfaces (Tyr 164 and Met 177 ) resulted in increased responsiveness to AMP. Overall, these findings may have implications in the design of novel FBPase inhibitors or activators.",
keywords = "allosteric enzyme, FBPase, fructose 1, 6-bisphosphatase deficiency, gluconeogenesis, renal cancer, type II diabetes",
author = "David Timson",
note = "{\circledC}2019 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY).",
year = "2019",
month = "3",
day = "6",
doi = "10.1042/BSR20190124",
language = "English",
volume = "39",
pages = "1--5",
journal = "Bioscience Reports",
issn = "0144-8463",
number = "3",

}

Fructose 1,6-bisphosphatase : getting the message across. / Timson, David.

In: Bioscience Reports, Vol. 39, No. 3, BSR20190124, 06.03.2019, p. 1-5.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Fructose 1,6-bisphosphatase

T2 - Bioscience Reports

AU - Timson, David

N1 - ©2019 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY).

PY - 2019/3/6

Y1 - 2019/3/6

N2 - Fructose 1,6-bisphosphatase (FBPase) is a key enzyme in gluconeogenesis. It is a potential drug target in the treatment of type II diabetes. The protein is also associated with a rare inherited metabolic disease and some cancer cells lack FBPase activity which promotes glycolysis facilitating the Warburg effect. Thus, there is interest in both inhibiting the enzyme (for diabetes treatment) and restoring its activity (in relevant cancers). The mammalian enzyme is tetrameric, competitively inhibited by Fructose 2,6-bisphosphate and negatively allosterically regulated by AMP. This allosteric regulation requires information transmission between the AMP binding site and the active site of the enzyme. A recent paper by Topaz et al. (Bioscience Reports (2019) 39, pii:BSR20180960) has added additional detail to our understanding of this information transmission process. Two residues in the AMP binding site (Lys 112 and Tyr 113 ) were shown to be involved in initiating the message between the two sites. This tyrosine residue has recently be shown to be important with protein’s interaction with the antidiabetic drug metformin. A variant designed to increase metal ion affinity (M248D) resulted in a five-fold increase in enzymatic activity. Interestingly alterations of two residues at the subunit interfaces (Tyr 164 and Met 177 ) resulted in increased responsiveness to AMP. Overall, these findings may have implications in the design of novel FBPase inhibitors or activators.

AB - Fructose 1,6-bisphosphatase (FBPase) is a key enzyme in gluconeogenesis. It is a potential drug target in the treatment of type II diabetes. The protein is also associated with a rare inherited metabolic disease and some cancer cells lack FBPase activity which promotes glycolysis facilitating the Warburg effect. Thus, there is interest in both inhibiting the enzyme (for diabetes treatment) and restoring its activity (in relevant cancers). The mammalian enzyme is tetrameric, competitively inhibited by Fructose 2,6-bisphosphate and negatively allosterically regulated by AMP. This allosteric regulation requires information transmission between the AMP binding site and the active site of the enzyme. A recent paper by Topaz et al. (Bioscience Reports (2019) 39, pii:BSR20180960) has added additional detail to our understanding of this information transmission process. Two residues in the AMP binding site (Lys 112 and Tyr 113 ) were shown to be involved in initiating the message between the two sites. This tyrosine residue has recently be shown to be important with protein’s interaction with the antidiabetic drug metformin. A variant designed to increase metal ion affinity (M248D) resulted in a five-fold increase in enzymatic activity. Interestingly alterations of two residues at the subunit interfaces (Tyr 164 and Met 177 ) resulted in increased responsiveness to AMP. Overall, these findings may have implications in the design of novel FBPase inhibitors or activators.

KW - allosteric enzyme

KW - FBPase

KW - fructose 1

KW - 6-bisphosphatase deficiency

KW - gluconeogenesis

KW - renal cancer

KW - type II diabetes

UR - http://www.scopus.com/inward/record.url?scp=85062560767&partnerID=8YFLogxK

U2 - 10.1042/BSR20190124

DO - 10.1042/BSR20190124

M3 - Article

VL - 39

SP - 1

EP - 5

JO - Bioscience Reports

JF - Bioscience Reports

SN - 0144-8463

IS - 3

M1 - BSR20190124

ER -